Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record.

Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission

Open access
Verheijen, René H., Massuger, Leon F., Benigno, Benedict B., Epenetos, Agamemnon A., Lopes, Alberto, Soper, John T., Markowska, Janica, Vyzula, Rostislav, Jobling, Tom, Stamp, Gordon, Spiegel, Gregory, Thurston, Dennis, Falke, Theo, Lambert, Joanna, Seiden, Michael V.·2006·Journal of Clinical Oncology

Abstract

Purpose: This was a multinational, open-label, randomized phase III trial comparing yttrium-90–labeled murine HMFG1 (90 Y-muHMFG1) plus standard treatment versus standard treatment alone in patients with epithelial ovarian cancer (EOC) who had attained a complete clinical remission after cytoreductive surgery and platinum-based chemotherapy. Patients and Methods: In total, 844 International Federation of Gynecology and Obstetrics stage Ic to IV patients were initially screened, of whom 447 patients with a negative second-look laparoscopy (SLL) were randomly assigned to receive either a single dose of 90 Y-muHMFG1 plus standard treatment (224 patients) or standard treatment alone (223 patients). Patients in the active treatment arm received a single intraperitoneal dose of 25 mg of 90 Y-muHMFG1 (target dose 666 MBq/m 2). The primary end point was length of survival; secondary end points included time to relapse and safety. The study had an 80% power to detect a 15% change in survival. Results: After a median follow-up of 3.5 years (range, 1 to 6 years), 70 patients had died in the active treatment arm compared with 61 patients in the control arm. Cox proportional hazards analysis of survival demonstrated no difference between treatment arms. In the study drug arm, 104 patients experienced relapse compared with 98 patients in the standard treatment arm. No difference in time to relapse was observed between the two study arms. Active therapy was associated with occasional grade 3 or 4 thrombocytopenia and neutropenia and grade 1 or 2 GI symptoms, abdominal discomfort, arthralgia, and myalgia. Conclusion: A single IP administration of 90 Y-muHMFG1 to patients with EOC who had a negative SLL after primary therapy did not extend survival or time to relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.5973

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 193

Metadata

Authors
Verheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., Markowska, J., Vyzula, R., Jobling, T., Stamp, G., Spiegel, G., Thurston, D., Falke, T., Lambert, J., & Seiden, M. V.
Venue
Journal of Clinical Oncology
Published
2006-02-01
Volume
24
Issue
4
Pages
571-578
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2115451334
Cited by
193
References
0
FWCI
16.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission. https://app.cochat.ai/papers/10.1200/jco.2005.02.5973
The paper
Verheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., Markowska, J., Vyzula, R., Jobling, T., Stamp, G., Spiegel, G., Thurston, D., Falke, T., Lambert, J., & Seiden, M. V. (2006). Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.5973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.